Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zielinski, Daniel C ^a   Filipp, Fabian V ^b,c   Bordbar, Aarash ^a,d   Jensen, Kasper ^e,h   Smith, Jeffrey W ^b   Herrgard, Markus J ^a,f   Mo, Monica L ^a,i   Palsson, Bernhard O ^a,g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Sinopia Biosciences   (United States)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^f Chalmers University of Technology   (Denmark)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

ⁱ WellSeek Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; GENISTEIN; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MELATONIN; METFORMIN; PENTOSE PHOSPHATE; POLYUNSATURATED FATTY ACID; SEROTONIN; UBIDECARENONE;

DRUG; GENE EXPRESSION; GENETIC VARIATION; GENOMICS; METABOLISM; PATHOLOGY;

ADVERSE DRUG REACTION; ARTICLE; CARBON METABOLISM; CATION TRANSPORT; CELL METABOLISM; CITRIC ACID CYCLE; DATA BASE; DIET SUPPLEMENTATION; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; FATTY ACID OXIDATION; GENE EXPRESSION; GENETIC ALGORITHM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; METABOLIC DISORDER; METABOLOMICS; MORBIDITY; NON PHARMACOKINETIC METABOLIC DYSREGULATION; OXIDATIVE STRESS; PARKINSONISM; PATHOGENESIS; PENTOSE PHOSPHATE CYCLE; PHARMACOGENOMICS; POLYAMINE SYNTHESIS; SIDE EFFECT; TARDIVE DYSKINESIA; TRANSCRIPTOMICS; UREA CYCLE; WEIGHT GAIN; FACTUAL DATABASE; PHARMACOGENETICS; VALIDATION STUDY;

DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACOGENETICS;

EID: 84931275672     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8101     Document Type: Article

References (62)

1. Mjorndal, T. et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol. Drug Saf. 11, 65-72 (2002).
2. Pirmohamed, M. et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329, 15-19 (2004).
3. Arrowsmith, J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329 (2011).
4. Arrowsmith, J. Trial watch: phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 87 (2011).
5. Loffler, W., Kilian, R., Toumi, M. & Angermeyer, M. C. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 36, 105-112 (2003).
6. Passarelli, M. C., Jacob-Filho, W. & Figueras, A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 22, 767-777 (2005).
7. Begaud, B., Martin, K., Fourrier, A. & Haramburu, F. Does age increase the risk of adverse drug reactions? Br. J. Clin. Pharmacol. 54, 550-552 (2002).
8. Pirmohamed, M. & Park, B. K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305 (2001).
9. Kuhn, M. et al. Systematic identification of proteins that elicit drug side effects. Mol. Syst. Biol. 9, 663 (2013).
10. Ong, S. E. et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl Acad. Sci. USA 106, 4617-4622 (2009).
11. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
12. Lee, S., Lee, K. H., Song, M. & Lee, D. Building the process-drug-side effect network to discover the relationship between biological processes and side effects. BMC Bioinformatics 12 (Suppl 2), S2 (2011).
13. Handschin, C. & Meyer, U. A. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55, 649-673 (2003).
14. Toyoshiba, H., Sawada, H., Naeshiro, I. & Horinouchi, A. Similar compounds searching system by using the gene expression microarray database. Toxicol. Lett. 186, 52-57 (2009).
15. Babcock, J. J., Du, F., Xu, K., Wheelan, S. J. & Li, M. Integrated analysis of drug-induced gene expression profiles predicts novel hERG inhibitors. PLoS One 8, e69513 (2013).
16. Wilke, R. A. et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6, 904-916 (2007).
17. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).
18. Colijn, C. et al. Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production. PLoS Comput. Biol. 5, e1000489 (2009).
19. Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl Acad. Sci. USA 104, 1777-1782 (2007).
20. Bordbar, A., Monk, J. M., King, Z. A. & Palsson, B. O. Constraint-based models predict metabolic and associated cellular functions. Nat. Rev. Genet. 15, 107-120 (2014).
21. Bordbar, A. & Palsson, B. O. Using the reconstructed genome-scale human metabolic network to study physiology and pathology. J. Intern. Med. 271, 131-141 (2012).
22. Lamb, J. et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
23. Orth, J. D., Thiele, I. & Palsson, B. O. What is flux balance analysis? Nat. Biotechnol. 28, 245-248 (2010).
24. Patil, K. R. & Nielsen, J. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proc. Natl Acad. Sci. USA 102, 2685-2689 (2005).
25. Brauer, M. J. et al. Conservation of the metabolomic response to starvation across two divergent microbes. Proc. Natl Acad. Sci. USA 103, 19302-19307 (2006).
26. Bradley, P. H., Brauer, M. J., Rabinowitz, J. D. & Troyanskaya, O. G. Coordinated concentration changes of transcripts and metabolites in Saccharomyces cerevisiae. PLoS Comput. Biol. 5, e1000270 (2009).
27. Mo, M. L., Palsson, B. O. & Herrgard, M. J. Connecting extracellular metabolomic measurements to intracellular flux states in yeast. BMC Syst. Biol. 3, 37 (2009).
28. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097 (2014).
29. Knox, C. et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).
30. Wulffele, M. G. et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 254, 455-463 (2003).
31. Chakraborty, A., Chowdhury, S. & Bhattacharyya, M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res. Clin. Pract. 93, 56-62 (2011).
32. Kimura, N. et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 20, 379-386 (2005).
33. Sala-Rabanal, M. et al. Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3. Mol. Pharm. 10, 1450-1458 (2013).
34. Kim, S. et al. Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol. Cell. Endocrinol. 220, 51-58 (2004).
35. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
36. Hindorff, L. A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362-9367 (2009).
37. Ramirez, A. H. et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 13, 325-329 (2012).
38. Jamshidi, Y. et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J. Am. Coll. Cardiol. 60, 841-850 (2012).
39. London, B. et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na + current and causes inherited arrhythmias. Circulation 116, 2260-2268 (2007).
40. Valdivia, C. R., Ueda, K., Ackerman, M. J. & Makielski, J. C. GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A. Am. J. Physiol. Heart Circ. Physiol. 297, H1446-H1452 (2009).
41. Danson, E. J., Choate, J. K. & Paterson, D. J. Cardiac nitric oxide: emerging role for nNOS in regulating physiological function. Pharmacol. Ther. 106, 57-74 (2005).
42. El-Demerdash, E. & Mohamadin, A. M. Does oxidative stress contribute in tricyclic antidepressants-induced cardiotoxicity? Toxicol. Lett. 152, 159-166 (2004).
43. Sansone, G. R., Matin, A., Wang, S. F., Bouboulis, D. & Frieri, M. Theophylline inhibits the production of nitric oxide by peripheral blood mononuclear cells from patients with asthma. Ann. Allergy Asthma Immunol. 81, 90-95 (1998).
44. Altug, S. et al. The role of nitric oxide in digoxin-induced arrhythmias in guinea-pigs. Pharmacol. Toxicol. 84, 3-8 (1999).
45. Sethi, R. et al. Antiarrhythmic effects of some antioxidant vitamins in rats injected with epinephrine. Cardiovasc. Toxicol. 9, 177-184 (2009).
46. Troyer, D. A., Schwertz, D. W., Kreisberg, J. I. & Venkatachalam, M. A. Inositol phospholipid metabolism in the kidney. Annu. Rev. Physiol. 48, 51-71 (1986).
47. Kitamura, H. et al. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int. 53, 146-153 (1998).
48. Ebbing, M. et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 302, 2119-2126 (2009).
49. Whitrow, M. J., Moore, V. M., Rumbold, A. R. & Davies, M. J. Effect of supplemental folic acid in pregnancy on childhood asthma: a prospective birth cohort study. Am. J. Epidemiol. 170, 1486-1493 (2009).
50. Lounkine, E. et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361-367 (2012).
51. Zhao, X. M. et al. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput. Biol. 7, e1002323 (2011).
52. Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
53. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
54. Zelezniak, A., Sheridan, S. & Patil, K. R. Contribution of network connectivity in determining the relationship between gene expression and metabolite concentration changes. PLoS Comput. Biol. 10, e1003572 (2014).
55. Thiele, I. et al. A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 31, 419-425 (2013).
56. Samaras, D. et al. Effects of widely used drugs on micronutrients: a story rarely told. Nutrition 29, 605-610 (2013).
57. Tiscornia, G., Vivas, E. L. & Izpisua Belmonte, J. C. Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat. Med. 17, 1570-1576 (2011).
58. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
59. Becker, S. A. & Palsson, B. O. Context-specific metabolic networks are consistent with experiments. PLos Comput. Biol. 4, e1000082 (2008).
60. Ahn, S. Y. et al. Linkage of organic anion transporter-1 to metabolic pathways through integrated 'omics'-driven network and functional analysis. J. Biol. Chem. 286, 31522-31531 (2011).
61. O'Donoghue, S. I. et al. Reflect: a practical approach to web semantics. J. Web Semant. 8, 182-189 (2010).
62. Schellenberger, J. et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0. Nat. Protoc. 6, 1290-1307 (2011).